Myriad Genetics (MYGN) Misses Q1 EPS by 2c; Maintains Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq hits intraday record high on Alphabet boost, Mideast negotiation hopes
- Exclusive: SB Energy Nasdaq IPO moving forward as planned
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Myriad Genetics Reports Fiscal First-Quarter 2017 Financial Results
November 1, 2016 4:05 PM EDTTotal Revenues of $177.5 MillionAdjusted EPS of $0.23 and Diluted EPS of ($0.02)Company Maintains Fiscal Year 2017 Financial Guidance and Issues Fiscal Second-Quarter 2017 Financial Guidance
SALT LAKE CITY, Nov. 01, 2016 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN) today announced financial results for its fiscal first-quarter 2017, provided an update on recent business highlights, Â maintained its fiscal year 2017 financial guidance and issued fiscal second-quarter 2017 financial guidance.Â
"We were pleased with the first quarter as our hereditary cancer business returned to more normal... More
